Top Page
Cogstate Ltd
(Sydney:CGS)
Cogstate Ltd (CGS) vs. iShares MSCI Australia ETF (EWA)
Cogstate Ltd Business Overview & Revenue Model
Cogstate Ltd Earnings Call Summary
Cogstate Ltd Financial Statement Overview
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 84.63M | 50.81M | 66.27M | 60.14M | 62.03M | 43.82M |
| Gross Profit | 42.32M | 30.69M | 37.60M | 12.29M | 21.63M | 10.40M |
| EBITDA | 26.58M | 16.93M | 9.90M | 8.46M | 18.07M | 8.21M |
| Net Income | 16.15M | 10.14M | 5.45M | 5.30M | 10.37M | 7.02M |
Balance Sheet | ||||||
| Total Assets | 64.77M | 64.77M | 57.84M | 81.22M | 84.99M | 68.44M |
| Cash, Cash Equivalents and Short-Term Investments | 35.56M | 35.56M | 45.11M | 43.08M | 44.50M | 31.49M |
| Total Debt | 469.92K | 469.92K | 672.72K | 569.21K | 2.05M | 2.32M |
| Total Liabilities | 16.88M | 16.88M | 25.33M | 24.60M | 37.12M | 39.43M |
| Stockholders Equity | 47.90M | 47.90M | 40.92M | 56.62M | 47.88M | 29.02M |
Cash Flow | ||||||
| Free Cash Flow | 18.91M | 8.40M | 7.12M | -1.53M | 8.54M | 17.24M |
| Operating Cash Flow | 19.40M | 11.48M | 10.00M | 1.76M | 13.45M | 21.61M |
| Investing Cash Flow | -4.85M | -2.24M | -1.68M | -3.29M | -4.91M | -3.52M |
| Financing Cash Flow | -5.98M | -3.79M | -4.91M | -1.33M | 1.05M | -246.11K |
Cogstate Ltd Technical Analysis
Cogstate Ltd Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $295.08M | 18.96 | 22.84% | 1.18% | 21.47% | 89.09% | |
56 Neutral | AU$30.01M | 110.00 | -253.44% | ― | -48.41% | -6520.00% | |
55 Neutral | AU$86.56M | ― | -8647.54% | ― | 25.98% | 21.43% | |
53 Neutral | AU$122.21M | 75.00 | -5.63% | ― | 10.06% | ― | |
51 Neutral | $7.91B | -0.36 | -41.70% | 2.23% | 23.45% | -1.86% | |
47 Neutral | AU$12.07M | ― | -27.84% | ― | 6.77% | -8.45% | |
40 Underperform | AU$103.52M | ― | ― | ― | ― |
Cogstate Ltd Corporate Events
Cogstate Ltd announced it will host its Financial Year 2025 Results webinar and a separate webinar on Alzheimer’s breakthroughs, highlighting its role in supporting clinical trials and commercialization in Alzheimer’s disease therapeutics. These events underscore Cogstate’s strategic positioning in the neuroscience technology industry, particularly in advancing Alzheimer’s disease drug development, which could have significant implications for stakeholders involved in biopharmaceutical research and healthcare.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd announced a correction to a previously released Change in Director’s Interest Notice for CEO Bradley O’Connor, rectifying a typographical error in the number of securities held. The corrected notice reflects an accurate total of 5,338,929 securities. This amendment ensures transparency and accuracy in the company’s disclosures, maintaining trust with stakeholders and compliance with ASX regulations.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Limited has announced a change in the director’s interest in securities, specifically involving Bradley O’Connor. The change includes the acquisition of 850,500 ordinary shares through the exercise of employee options, resulting in a total of 5,388,929 ordinary shares held by the director. This adjustment reflects a strategic move in the company’s governance, potentially impacting stakeholder perceptions and the company’s market positioning.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has announced the issuance of 850,500 fully paid ordinary securities, which will be quoted on the Australian Securities Exchange (ASX) as of July 9, 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase its capital for future growth, signaling a positive step for stakeholders and investors.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has updated its Securities Trading Policy, as announced by the Board of Directors. This revision aligns with ASX Listing Rule 12.10 and reflects the company’s commitment to maintaining robust governance practices. The update is part of Cogstate’s ongoing efforts to enhance its operational framework, potentially impacting its market positioning and stakeholder confidence.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has upgraded its financial guidance for the fiscal year ending June 30, 2025, citing strong performance and an improved outlook. The company anticipates a significant revenue increase of 20% to 24% compared to the previous year, with full-year revenue expected to reach between $52 million and $54 million. Profit before tax is also projected to rise substantially, with an improvement of 69% to 97% over the prior year. This positive financial outlook reflects Cogstate’s strengthened position in the neuroscience technology industry, potentially benefiting stakeholders and enhancing its market presence.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd announced its first webinar in the Investor Insights Series, highlighting its partnership with Medidata to drive innovation in Central Nervous System (CNS) research. This collaboration aims to enhance clinical trial outcomes through Medidata’s advanced platform and Cogstate’s expertise in cognitive assessment, benefiting sponsors, researchers, and patients. The series is designed to expand investor engagement and understanding of Cogstate’s role in CNS research, with future webinars focusing on Alzheimer’s breakthroughs and the company’s central position in supporting clinical trials and commercialization.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company is set to quote a total of 148,220 ordinary fully paid securities, with various issue dates in May and June 2025. This move is part of the company’s strategy to enhance its market presence and potentially increase liquidity for its stakeholders.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd announced the cessation of certain securities, specifically performance rights, due to the lapse of conditional rights that were not satisfied. This development may impact the company’s capital structure and could have implications for stakeholders, as it reflects adjustments in the company’s securities management.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has launched a new InvestorHub to enhance shareholder engagement and provide strategic insights and updates. This initiative positions Cogstate to capitalize on growth opportunities in CNS disease research, leveraging its partnership with Medidata to drive innovation in clinical trials. The InvestorHub will also host the Investor Insight Series, featuring events to broaden investor reach and highlight collaborations that improve trial outcomes.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Limited, a company listed on the Australian Securities Exchange (ASX), has experienced a change in the interests of a substantial shareholder. Australian Ethical Investment Limited has increased its voting power in Cogstate from 9.63% to 10.64%, indicating a growing interest and potential influence in the company’s decision-making processes.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.45 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd announced the retirement of Mr. Richard van den Broek as a non-executive director, who has been with the company since 2010 and was its first USA-based non-executive director. Mr. van den Broek, a former healthcare analyst and experienced investor in the pharma/biotech market, has significantly contributed to the company through his knowledge of drug development pipelines and industry trends. His departure comes at a time when Cogstate is experiencing exciting technological advancements in cognitive measurement, and he will remain a shareholder and advisor to the company.
The most recent analyst rating on (AU:CGS) stock is a Buy with a A$1.80 price target. To see the full list of analyst forecasts on Cogstate Ltd stock, see the AU:CGS Stock Forecast page.
Cogstate Ltd has announced an update regarding its ongoing on-market buy-back program, with a total of 210,288 ordinary fully paid securities bought back on the previous day, adding to the cumulative total of 5,571,816 securities repurchased. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially enhance shareholder value, reflecting a proactive approach in managing its financial resources.
Cogstate Ltd has announced an update regarding its ongoing on-market buy-back program, which involves the repurchase of its ordinary fully paid securities. As of the latest update, the company has bought back a total of 5,571,816 securities, including 56,526 on the previous day. This buy-back initiative is part of Cogstate’s strategy to manage its capital structure and potentially enhance shareholder value.
Cogstate Ltd has announced an update regarding its ongoing on-market buy-back program. As of May 7, 2025, the company has repurchased a total of 5,515,290 ordinary fully paid securities, including 92,427 securities bought back on the previous day. This buy-back initiative is part of Cogstate’s strategy to manage its capital structure and potentially enhance shareholder value.
Cogstate Ltd has announced an update on its ongoing on-market buy-back program, indicating the purchase of 118,642 ordinary fully paid securities on the previous day, bringing the total number of securities bought back to 5,278,873. This buy-back initiative is part of the company’s strategy to manage its capital structure and potentially enhance shareholder value.